Form 4: C4 Therapeutics Chief Legal Officer Reports Stock Transactions

Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports the vesting and tax withholding of performance restricted stock units.

Summary

• On November 7, 2024, Jolie Siegel, the Chief Legal Officer of C4 Therapeutics, engaged in transactions involving the company's common stock.
• Siegel acquired 3,750 shares of common stock through the vesting of performance restricted stock units (PRSUs).
• 1,102 shares were withheld by C4 Therapeutics to satisfy tax obligations related to the vesting of the PRSUs.
• Following these transactions, Siegel directly owns 56,488 shares of C4 Therapeutics common stock.
• Siegel also holds 10,500 performance restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders.
• Vesting schedules and performance-based equity awards are standard components of executive compensation packages in comparable companies.
• Similar filings are regularly made by officers and directors of publicly traded companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.

Stakeholder Impact

• The transactions have a minor impact on shareholders, reflecting changes in insider ownership.
• The vesting of PRSUs incentivizes the Chief Legal Officer to contribute to the company's success.

Key Dates